CelLBxHealth plc · LSE:CLBX
CelLBxHealth — ANGLE — H1 2023 Earnings Presentation
19 slides from CelLBxHealth's earnings presentation, Sep 7, 2023
Slide 1: Transforming cancer care with the first FDA cleared medical device
Transforming cancer care with the first FDA cleared medical device for the capture and harvest of circulating tumour cells Interim Results for the six months ended 30 June 2023 Andrew Newland and Ian Griffiths 7 September 2023
Slide 2: Legal disclaimer
LSE AIM: AGL OTCQX: ANPCY Legal disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The presentation slides which follow this notice and the oral presentation of whi
Slide 3: ANGLE – Transforming cancer care
ANGLE – Transforming cancer care Our Mission: Parsortix® instrument Enable personalized cancer care with INTENDED USE a simple blood test to guide The Parsortix® PC1 system is an in vitro diagnostic device treatment, improving patient intended to enrich circulating tumor cells (CTCs) from outcomes a
Slide 4: First Half Highlights
First Half Highlights Revenue growth and continued careful cash control Half year Post period end • Revenue trebled to £1.2 million in line with market • Further encouraging results from testing of expectations, reflecting beginning of growth trajectory market leading molecular platforms anticipated
Slide 5: Financial Results for the six months ended June 2023
Financial Results for the six months ended 30 June 2023 Six months ended Six months ended Year ended 30 June 2023 30 June 2022 31 December 2022 Key highlights: £'000 £'000 £'000 • Strong growth in revenues, trebled year on Statement of Comprehensive Income year Revenue 1,196 419 1,041 Cost of sales
Slide 6: Commercial strategy
Commercial strategy Integrated model with experienced leadership Business areas Brett Swansiger Chief Commercial Officer Over 20 years of commercial leadership • Product business experience within the molecular – expanding existing diagnostics and pharmaceutical industries. research sales to Brett s
Slide 7: Products - sales and distribution network being established
Products - sales and distribution network being established for international penetration • Direct sales team being expanded in United States and UK • Distribution partners selected for other key territories based on: – local knowledge and language – exposure to oncology markets – compliance with qu
Slide 8: Services - differentiated pharma services offering
Services - differentiated pharma services offering • Customer base established and growing Examples: – multiple customers, repeat business – new customers in 2023 and growing pipeline Large US pharma US biotech customer customer • Clinical stage immuno- • Significant revenue and profitability potent
Slide 9: Content - assay development for products and services
Content - assay development for products and services Product business area Imaging Assays Molecular Assays Product kits, Research and Immunofluorescent Molecular analysis of reagents and Distributors clinical laboratory staining of CTCs CTCs including: protocols customers including: • Portrait Flex
Slide 10: Content – 'Portrait' imaging assays for pharma services
Content – ‘Portrait’ imaging assays for pharma services Portrait Flex Portrait DDR Portrait PD-L1 For detection of epithelial, mesenchymal, For detection of epithelial, For detection of PD-L1 on epithelial, and blood cells markers and additional mesenchymal, and blood cells markers mesenchymal and t
Slide 11: Content – 'Portrait+' product kit for distribution
Content – ‘Portrait+’ product kit for distribution Antibody kit for robust and consistent imaging by Parsortix customers includes: • Antibodies directly conjugated and mixed into a single vial: – Epithelial markers – Mesenchymal markers – Blood lineage markers • Lyophilised for shipping and storage
Slide 12: Content – HER2 assay collaboration with BioView
Content – HER2 assay collaboration with BioView • Breast cancer is highly heterogeneous and HER2 status can change over time 80.2% • New antibody-drug conjugates (ADCs) to treat patients with low HER2 status Predicted increase in global cases of breast cancer from 2020 to 2040 • Significant need for
Slide 13: Content – molecular analysis platforms under evaluation
Content – molecular analysis platforms under evaluation DNA • Variety of third-party ThermoFisher sequencing platforms and Next Generation Illumina profiling kits demonstrated to Sequencing (NGS) detect variants in CTCs from High-Multiplex RNA Parsortix harvests NanoString RNA-Seq • CTC/ctDNA isolat
Slide 14: Content – molecular analysis of CTCs and ctDNA
Content – molecular analysis of CTCs and ctDNA • CTCs can be analysed by downstream molecular Patient with metastatic SCLC to bone and brain methods for variant detection and CTCs and ctDNA profiled using Illumina NGS pan- transcriptomic profiling cancer panel covering 61 genes and 360 hotspots • Hi
Slide 15: Clinical studies building sample bio-bank for analysis
Clinical studies building sample bio-bank for analysis INFORM - Metastatic DOMINO - Prostate pilot Cancers (breast, prostate, ovarian, EMBER2 - Pelvic mass lung) study with Solaris Health Objective: Assay development / Parsortix Objective: Verification of performance Objective: Cancer presence and s
Slide 16: Growing body of evidence
Growing body of evidence Leveraged R&D strategy identifying new applications • FDA clearance expected to help At 31 August 2023 Parsortix become the CTC system of choice CTC clusters 76 published in Biopsy surrogate in • Installed base of over 290 Parsortix systems in active use metastatic cancer Me
Slide 17: Eight new peer-reviewed publications in H1
Eight new peer-reviewed publications in H1 • Frontiers in Oncology: “The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer” • Cancer Cell International: “The role of the desmosomal protein desmocollin 2 in tumour progres
Slide 18: Outlook
Outlook Strong growth in 2023 and beyond • Revenue growth trajectory expected to continue in H2 and beyond in line with market expectations – New pharma services customers anticipated, including large pharma – Kits to support instrument and consumable sales • Year-end cash expected ahead of forecast
Slide 19: ANGLE plc contact details
ANGLE plc ANGLE Europe Ltd 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom ANGLE North America Inc 5100 Campus Drive Suite 120 Plymouth Meeting PA 19462 USA www.angleplc.com 19